Sanofi’s Altuviiio Set To Reenergize Factor VIII Space
The once-weekly Factor VIII replacement therapy for hemophilia A, newly approved by the US FDA, appears well positioned to compete with Roche’s blockbuster Hemlibra.
You may also be interested in...
Some analysts have expressed concern in the past about the French drugmaker’s product launchpad but CEO Paul Hudson has dismissed such claims, pointing to the spectacular lift off of Beyfortus.
The big pharma is building on its hematology legacy beyond coagulation factors with marstacimab and gene therapies for hemophilia, plus oral and injectable medicines for sickle cell disease.
The drug showed efficacy in hemophilia A and B with no sign of clots, an issue that historically has dogged anticoagulation agents, but it remains unclear whether that advantage will hold.